Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review

Background: Lung adenocarcinoma with the classical EGFR 19 deletion and exon 21 L858R point mutations has exhibited good responses to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. However, the sensitivity of uncommon EGFR exon 20 insertion mutation to third-gener...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiao, Han, Huan, Zhao, Jiuzhou, Liu, Xiao, Zhang, Jianbo, Sun, Rui, Li, Shaomei, Liu, Baoxing, Zhu, Hui, Jiao, Shuyue, Li, Xiang, Tang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9432720/
https://www.ncbi.nlm.nih.gov/pubmed/36059942
http://dx.doi.org/10.3389/fphar.2022.964606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9432720/
https://www.ncbi.nlm.nih.gov/pubmed/36059942
http://dx.doi.org/10.3389/fphar.2022.964606

Ejemplares similares